Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers. However, the optimal duration of immunotherapies is currently unknown. Our hypothesis is that a reduced dose intensity of IO could be as effective as the current standard treatment in term of prevention of the disease progression. If proved right, this study will have a positive medico-economic impact by reduction of the costs associated with the treatment and the toxicity, and an increase of the patients

Trial Details

NCT ID
NCT05078047
Phase
PHASE3
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Reduced dose intensity of IO
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Avignon, France|43.94834,4.80892
  • Bayonne, France|43.49316,-1.473
  • Besançon, France|47.24878,6.01815
  • Bordeaux, France|44.84124,-0.58046

Key Eligibility Criteria

  • Patients must have signed a written informed consent form prior to any trial specific procedures.
  • Patient aged ≥18 years old.
  • Metastatic disease (or locally advanced disease not suitable for local treatment) of initial tumor histologically confirmed including: lung cancer,…
  • Patients in partial or complete response after 6 months of standard immunotherapy (whatever the line of therapy) according to the RECIST or PERCIST…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →